Acute myocardial infarction: treatment with thrombolytic therapy.
The past 5 years have witnessed an explosion in the amount of published clinical trial data for the use of intravenous thrombolytic therapy for acute myocardial infarction. This article reviews the properties of the various agents, the experiences of each in prospective, randomized clinical trials, and the future directions of thrombolytic intervention.
Topol
E J
EJ
Cardiac Catheterization Laboratories, University of Michigan Medical Center, Ann Arbor.
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000187:drug effects; D015912:Thrombolytic Therapy / Q000592:standards*
D005343:Fibrinolytic Agents